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Abstract: Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Nearly 50%
of the patients who receive the most intensive treatment develop chemoresistant leukemia relapse.
Although the leukemogenic events leading to relapse seem to differ between patients (i.e., regrowth
from a clone detected at first diagnosis, progression from the original leukemic or preleukemic
stem cells), a common characteristic of relapsed AML is increased chemoresistance. The aim
of the present study was to investigate at the proteomic level whether leukemic cells from
relapsed patients present overlapping molecular mechanisms that contribute to this chemoresistance.
We used liquid chromatography–tandem mass spectrometry (LC–MS/MS) to compare the proteomic
and phosphoproteomic profiles of AML cells derived from seven patients at the time of first
diagnosis and at first relapse. At the time of first relapse, AML cells were characterized by increased
levels of proteins important for various mitochondrial functions, such as mitochondrial ribosomal
subunit proteins (MRPL21, MRPS37) and proteins for RNA processing (DHX37, RNA helicase;
RPP40, ribonuclease P component), DNA repair (ERCC3, DNA repair factor IIH helicase; GTF2F1,
general transcription factor), and cyclin-dependent kinase (CDK) activity. The levels of several
cytoskeletal proteins (MYH14/MYL6/MYL12A, myosin chains; VCL, vinculin) as well as of proteins
involved in vesicular trafficking/secretion and cell adhesion (ITGAX, integrin alpha-X; CD36, platelet
glycoprotein 4; SLC2A3, solute carrier family 2) were decreased in relapsed cells. Our study introduces
new targetable proteins that might direct therapeutic strategies to decrease chemoresistance in
relapsed AML.
Keywords: acute myeloid leukemia; proteome; phosphoproteome; markers; patient relapse;
mass spectrometry; kinase; minimal residual disease; mitochondria; CDK; degranulation; secretion
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1. Introduction
Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy [1–3].
Although most patients with newly diagnosed AML achieve complete remission (CR) after intensive
induction and consolidation therapy, more than half of them relapse within the next three years.
Late relapse (i.e., after five years of remission) is very uncommon [4]. The overall long-term AML-free
survival is, therefore, only about 50%, even for young and fit AML patients who tolerate intensive
therapy [5].
Relapses derive from minimal residual disease (MRD) [6–8] developing from the original
dominating clone, from a minor subclone, or through progression from the original leukemic or
preleukemic stem cells [9–11]. Regardless of the origin, AML relapsed cells have an increased
chemoresistance in common [5]. Relapsed AML patients are usually treated with salvage
cytotoxic therapy, but current clinical trials test pathway-targeted agents and immunotherapy-based
approaches [12]. Such approaches depend on the knowledge of potential therapeutic targets in relapsed
AML cells. [13–15].
Two separate whole-exome sequencing (WES) studies performed with paired patient samples
at diagnosis and at early or late relapse, respectively [16], showed that the patients presented
different genetic events leading to relapse. Relapsed AML had usually acquired at least one
relapse-specific mutation (e.g., in FLT3, ASXL1 or RUNX1), whereas mutations in NPM1 and in
signaling genes (e.g., NRAS, KIT, PTPN11) were less frequent [17,18]. These observations further
illustrated the heterogeneity of AML with regard to new leukemogenic events prior to the development
of chemoresistant AML relapse.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) technology has been applied
to the study of AML blasts at relapse compared to diagnosis in 10 patients [13,19]. The levels of
several proteins involved in DNA repair were significantly increased, and signaling proteins such
as KIT and STAT5 were significantly more phosphorylated in relapsed cells. Various molecules
involved in survival, apoptosis, and metabolism were also modulated, but these observations were
patient-specific. In a previous study, we utilized LC–MS/MS-based proteomics/phosphoproteomics
and the super-SILAC (Stable Isotope Labeling with Amino acids in Cell culture) mix quantitation
approach to compare the proteome and phosphoproteome of AML cells derived at the time of first
diagnosis from patients who later became leukemia-free survivors to those of AML cells acquired from
patients who relapsed after an initial intensive and potentially curative treatment [20]. In our present
study, we used the same methodological approach to compare proteomic and phosphoproteomic
profiles for paired samples derived at the first time of diagnosis and at later first relapse. All samples
were prepared according to the same standardized guidelines, and the enrichment of AML cells was
carefully controlled. The aim of the study was to investigate whether patients with leukemia relapse
show similarities in their proteomic and phosphoproteomic profiles despite the previously described
leukemogenic heterogeneity of AML relapse [9–11].
2. Results
2.1. Description of AML Patients and Patients’ Cells Included in the Study
We investigated paired peripheral blood AML cell samples derived from seven patients at
the time of first diagnosis (DIAGNOSIS samples) and at the time of first relapse (FIRST RELAPSE
samples) (Figure 1).
To ensure that our patients were comparable, all samples included in the present study had to
fulfill the following criteria: (i) a high percentage of AML cells among peripheral blood leukocytes both
at the time of first diagnosis and at the time of first relapse; (ii) enriched AML cell populations including
at least 90% of leukemic cells (documented both by microscopy and by flow cytometry) could thereby
be prepared by highly standardized density gradient separation of viable cell suspensions [20]; (iii) all
samples were thus derived from the same in vivo compartment, i.e., peripheral blood; and (iv) ex vivo
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handling of all blood samples was in accordance with the same standardized guidelines. We could
thereby ensure a similar and high quality of all first diagnosis and first relapse samples included in
the present study.
Figure 1. Overview of the matched diagnosis–first relapse patient cohort. The study included
paired acute myeloid leukemia (AML) cell samples from seven patients, collected at the times of first
diagnosis (DIAGNOSIS) and first relapse (FIRST RELAPSE). All patients received intensive induction
chemotherapy and consolidation therapy and achieved complete remission (CR) (Table 1). All relapses
occurred within three years after CR.
















PX1 ICT/CCT 2 8 ICT No CR2, death fromchemoresistant disease 3
PX2 ICT/CCT 1 16 ST No CR2 1
PX3 ICT/CCT 1 27 ICT
Allogeneic
retransplantation in CR2,
death due to chemoresistant
second relapse
10
PX4 ICT/CCT 1 13 ST No CR2 2
PX5 ICT/CCT 1 5 ICT




PX6 ICT/CCT 1 3 ICT No CR2, death fromchemoresistant disease 2
PX7 ICT/CCT 2 2 ICT No CR2 3
CR: 1, first remission; 2, second remission; ICT: induction chemotherapy; CCT: consolidation chemotherapy; ST:
supportive therapy.
The first relapse occurred less than three years after the patients achieved CR. Clinical progression
after CR is shown in Table 1 and described in Materials and Methods. Genetic analysis of paired
DIAGNOSIS–FIRST RELAPSE samples was available for six patients and revealed several overlapping
mutations. However, one patient acquired the mutation FLT3-ITD and another RUNX1 + del (7q)
at first relapse, while the relapsed AML cells of one patient no longer contained the abnormalities
(FLT3-TDK, IDH2, BCOR) present at the time of first diagnosis (Table S1).
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2.2. Mitochondrial Processing and Immune Responses at Relapse
The proteome profiles of AML patient cells derived from seven paired DIAGNOSIS–FIRST
RELAPSE samples obtained using the super-SILAC mix approach allowed us to quantitatively
determine the expression of 4132 proteins, against 3747 proteins using label-free (LF) quantitative
proteomics (File S1), when including only proteins that yielded reliable FIRST RELAPSE/DIAGNOSIS
fold change (FC) values for at least five out of the seven patients. The FC of the 3348 proteins quantified
by the two quantification methods correlated well (Pearson r = 0.675; p < 0.0001; Figure S1).
The present DIAGNOSIS–FIRST RELAPSE proteome and phosphoproteome datasets, based on
the super-SILAC mix results, were compared with those described in a larger cohort of AML samples
collected at the time of first diagnosis from patients that either relapsed or had been AML-free for at
least 5 years [20]. Few proteins and phosphorylation sites overlapped in both studies (Figure S2a,b),
showing that the proteome and phosphoproteome changed considerably from the first diagnosis to
the first relapse. We observed zinc finger proteins and phosphorylated RNA-binding proteins among
the overlapped factors. The FC of expression and of phosphorylation had the same direction with
regard to relapsed samples for all overlapping proteins and phosphorylated sites.
Separate statistical analysis of the labeled proteomic and phosphoproteomic datasets indicated
168 differentially expressed proteins and 77 differentially regulated phosphorylation sites, respectively
(Files S1 and S2). Mitochondrial proteins were significantly enriched at first relapse (Figure 2a, left part),
such as 28S ribosomal proteins (Figure 2c, Cluster 1), mitochondrial respiratory chain complex proteins,
and proteins involved in mitochondrial metabolism (Table S2). Nucleolar, nucleic acid-binding, and nucleic
acid metabolism proteins were more phosphorylated at first relapse (Figure 2b, left part). Exocytosis
and secretion as well as membrane and vesicle proteins were more abundant and phosphorylated,
respectively, at diagnosis (Figure 2a,b, right part).
A protein–protein interaction (PPI) network of the differentially expressed proteins confirmed
the increased abundance of mitochondrial, ribosomal, mRNA-, rRNA-, and tRNA-processing factors
(Figure 2c, Cluster 1–4) at first relapse. RNA-splicing and -binding proteins were also more
phosphorylated at first relapse (Figure 2d, Cluster 1,2).
Proteins with decreased cellular expression at the time of first relapse formed clusters of functional
interaction (Figure 2c, Cluster 5–7) for neutrophil degranulation, platelet degranulation, and actin
cytoskeleton (for details see Table S3). It should be noted (see also the Discussion section) that several
of the proteins belonging to the neutrophil and platelet degranulation clusters are also important
for the intracellular trafficking of endosomes or secretory vesicles [21] and that the cytoskeleton is
important not only for endogenous cell function, but also for signaling initiated by cell surface adhesion
molecules [22,23].
The phosphoproteomes indicated, based on iceLogo [24] analysis of the amino acid sequences
surrounding the differentially regulated phosphorylation sites, an increase of proline-directed
and basophilic motifs in the FIRST RELAPSE group (Figure 3a), suggesting higher activating
phosphorylation of mitogen-activated protein kinases (MAPKs) and cyclin-dependent kinases (CDKs),
respectively. In the DIAGNOSIS group, an increase was noted for basophilic motifs located prior to
the phosphorylation site characteristics of cAMP-dependent protein kinase catalytic subunit alpha
(PRKACA) and protein kinase C family (PRKC).
A separate kinase-substrate enrichment analysis (KSEA) [25,26], using non-differentially regulated
phosphorylation sites as background, supported an increased activity of CDKs in the FIRST RELAPSE
group and of PRKACA, PRKC, and serine/threonine protein kinase PAK2 in the DIAGNOSIS
group (Figure 3b).
Western blot analyses using lysates from six DIAGNOSIS–FIRST RELAPSE paired patient cells
showed higher phosphorylation of CDK2 T160 in the FIRST RELAPSE samples (Figure S3), although
the difference between the paired groups was at the limit of statistical significance (p = 0.0625).
These findings correlate well with the kinase-substrate motif analyses showing higher relative
abundance of phosphorylated CDK2 substrates in the FIRST RELAPSE group.
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Figure 2. The AML proteome and phosphoproteome are enriched in mitochondrial ribosomal,
RNA-processing, and DNA repair proteins at first relapse. Gene ontology (GO) analysis was conducted
for the proteome (a) and phosphoproteome (b), separately. Top 10 enriched GO categories are shown
on the y-axis of each bar plot. The -log10 p values and the number of proteins associated with these GO
categories are shown on the X-axis. Dashed bars represent GO categories that are also significantly
enriched with false discovery rate (FDR) < 0.05. (c,d) Networks of protein–protein interactions
(PPI) based on STRING search of the proteomic and phosphoproteomic datasets and visualized in
Cytoscape after ClusterONE analysis. Significance of high cohesiveness of protein and phosphoprotein
networks is shown by the p value of a one-sided Mann–Whitney U test. Fold changes (FCs) of protein
expression or phosphorylation according to the super-SILAC (Stable Isotope Labeling with Amino
acids in Cell culture) mix method are color-coded; orange-colored proteins showed a higher expression
or phosphorylation in the FIRST RELAPSE group, and Yale blue-colored proteins showed a higher
expression or phosphorylation in the DIAGNOSIS group. The differentially regulated phosphorylation
site(s) is shown next to each phosphoprotein.
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Figure 3. AML phosphoproteome in the FIRST RELAPSE group is enriched with cyclin-dependent
kinases (CDKs) substrates. (a) Sequence motif analysis of the ± 31 amino acids flanking the differentially
regulated phosphorylation sites (indicated with a black arrow) for the FIRST RELAPSE and DIAGNOSIS
groups. (b) Kinase-substrate enrichment analysis (KSEA) of differentially regulated and unregulated
phosphorylation sites. The kinase z-score (X axis) is the normalized score for each kinase (Y axis),
weighted by the number of identified substrates.
3. Discussion
Although stable remission can be induced by intensive antileukemic therapy for a majority of
young and fit patients, about half of them relapse with chemoresistant AML [5]. AML cells from
relapsed patients have been analyzed by whole-genome sequencing (WGS) or WES, but the protein
and phosphoprotein patterns associated with AML relapse are less studied [16,27,28].
We have recently reported the proteomic and phosphoproteomic profiles of AML cells
derived from patients at the first diagnosis before any antileukemic treatment [20]. The paired
DIAGNOSIS–FIRST RELAPSE samples of the present study revealed significant alterations of
the proteome and phosphoproteome between primary (diagnosis point) AML cells and the relapsed
AML cells.
Our institution is responsible for the diagnostic evaluation and treatment of AML patients from a
defined geographical area, including patients with relapsed disease. Our priority in the present study
was not to include all patients during a defined time period, but to include all relapsed patients for
whom it was possible to obtain AML cell samples that fulfilled our predefined quality criteria both
at the time of first diagnosis and at the time of first relapse. Following the detection of AML relapse,
antileukemic treatment has to be started for our patients, without additional delay [29]. Thus, for many
of them it is not possible to prepare highly enriched AML cell populations that fulfill our quality
criteria without extensive cell separation procedures that may influence the biological characteristics of
the cells [30]. For these reasons, many of our relapsed patients could not be included in our present
study. Despite this, it may be justified to say that our study is population-based, i.e., we included
all relapsed patients from a defined geographical area and during a defined time, for whom AML
cell samples fulfilling predefined quality criteria could be prepared both at the time of first diagnosis
and the time of chemoresistant first relapse. Because of the full description of AML patients and their
samples provided here, our present study should therefore be regarded as the first published complete
report about a selection of high-quality samples that allowed reliable observations.
Analyses of GO categories showed higher expression of mitochondrial proteins in the FIRST
RELAPSE group. This may be an adaption to the high level of lactate in advanced cancers
and the leukemic bone marrow. Mitochondria may also contribute to drug resistance, since inhibitors
of mitochondrial protein translation like tigecycline and tedizolid could restore drug sensitivity in
human leukemic cell lines, suggesting a potential for the targeting of mitochondrial protein synthesis
to treat AML [31–34]. RNA transcription and translation processes were also upregulated in the FIRST
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RELAPSE group. This observation is especially significant, since the levels of proteins associated with
RNA transcription and translation were higher already at diagnosis for those patients that did relapse
later [20]. It appears, therefore, that a high AML cell capacity for protein translation is associated
with an increased relapse risk. A previous proteome and functional study showed that AML cells
exposed in vitro to anthracycline responded with increased synthesis of survival proteins and became
sensitized to death by protein synthesis inhibitors [35].
The AML proteome in the FIRST RELAPSE group had significantly decreased expression of
proteins associated with the plasma membrane, exocytosis and secretory vesicles, as well as cytoskeletal
proteins. A similar trend was noted when comparing the AML cell proteome at the first time of
diagnosis from patients who later develop AML relapse and who become long-term AML-free survivors
(i.e., at least a five-year survival) [20]. The NFκB transcription factor was also downregulated in
the FIRST RELAPSE group. This protein appears to stimulate the transcription of several cytokines
in AML cells, and its decreased expression may contribute to the observed lowered cytokine gene
transcription in relapsed cells [36–38].
The downregulation of cytokines and cytoskeleton components contributing to intracellular
endosomal trafficking and extracellular release of soluble mediators by secretory vesicles [39] indicate
that relapsed or relapse-prone AML cells have decreased capacity of and probably need for normal
intercellular signaling and contacts. This notion is supported by a previous study of the constitutive
cytokine secretion profile during in vitro culture of AML patient cells [40,41], which showed that
the low constitutive release of 41 soluble mediators was associated with unfavorable prognosis after
intensive therapy. Thus, our findings are consistent with the hypothesis that chemoresistant AML cells
are less dependent on the support from neighboring nonleukemic stromal cells mediated through
the local cytokine network or through adhesion to the extracellular matrix or to neighboring stromal
cells mediated by integrins or other adhesion molecules.
The alignment of amino acid sequences surrounding phosphorylation sites and KSEA showed
enrichment of CDK substrates in the FIRST RELAPSE group. A similar kinase–substrate prediction
scenario was observed in relapsed patients studied at diagnosis [20]. CDK inhibitors are currently
investigated as a promising therapeutic strategy either in newly diagnosed or in relapsed AML
cases [42–44]. The high CSK2 kinase activity of relapsed patients at diagnosis was no longer
observed in chemoresistant cells after relapse. This may be explained if CSK2 has a role in
inducing treatment-resistant clones but is dispensable for the survival of clones that already have
become therapy-resistant. As observed for the relapse-free patients characterized at diagnosis [20],
the phosphoproteome analysis in this study revealed activation of PRKA/C and PAK kinases in
the DIAGNOSIS group.
A final point is whether the technologies used in the present study are suitable for routine
clinical practice. The first question is then whether it is realistic to obtain sufficient leukemic cells
for such analyses. In our experience, 20 µg of protein is needed for proteomic and at least 200 µg
for phosphoproteomic analyses. We usually retrieve 5–15 × 106 cells from each of our samples.
Thus, it should be possible to achieve sufficient material for most patients. Secondly, will the results
from such analyses be available before the antileukemic treatment is planned to start? In our
experience, results from proteomic analyses can be available within three days, and phosphoproteomic
results within four days, but this time can probably be shortened when the analyses are robotized.
This is within the recommended time limit for the start of intensive antileukemic therapy [29].
Thirdly, this methodological approach should be possibly independent of the morphology or genetic
abnormalities of AML cells. Finally, proteomic analyses should be carried out with regard to
the prognostic evaluation of patients or as a guide for the selection of targeted therapies, whereas
we would expect the analysis of AML-specific markers (e.g., genetic abnormalities) or single cell
analyses to be more appropriate for the analysis of MRD [45,46]. Thus, although LC–MS/MS-based
technologies could be suitable for clinical AML analysis, one should emphasize that additional clinical
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studies, standardization of the methods, and probably also development of faster bioinformatical tools
will be required for a clinical implementation of such analyses.
4. Materials and Methods
The materials and methods of this study will be described briefly. Detailed workflows can be
found in a previous publication of our group [20].
4.1. AML Patients and Sample Collection
Written informed consent was obtained from all patients in accordance with the Declaration
of Helsinki. The use of human leukemia cells for the present study was approved by the Regional
Ethics Committee (REK III Vest 2013-634). Primary AML cells were collected from the peripheral
blood of patients with circulating leukemia blasts representing > 80% of circulating leukocytes, both at
the first diagnosis (DIAGNOSIS) prior to treatment and at the time of first relapse (FIRST RELAPSE).
The peripheral blood leukocyte counts are given in Table S1. Highly enriched (generally > 95%) AML
cell populations were isolated by density gradient separation (Lymphoprep, Axis-Shield, Dundee,
Scotland) [47]. This and other methodological strategies were described and discussed previously [20].
All patients received intensive induction and consolidation treatment leading to stable first CR,
before relapse of the disease. They represented a consecutive (and thereby random) group of patients
admitted to our hospital, fulfilling the following criteria: completed previous intensive antileukemic
treatment, early relapse (i.e., within 27 months), and sufficient level of circulating AML cells for analysis
at the time of both first diagnosis and first relapse. No samples were influenced by recent or ongoing
anti-leukemic therapies.
All our patients received either intensive or supportive chemotherapy after diagnosis of first
relapse. Six of them did not achieve a second CR and died within three months after diagnosis of first
relapse. The remaining patient that achieved a second CR had allogeneic stem cell transplantation but
died 10 months after first relapse (Table 1). The results of the mutational analysis of 54 genes frequently
mutated in AML in the DIAGNOSIS and FIRST RELAPSE samples are shown in Table S1. The method
for the genetic analyses has been described somewhere else [48].
4.2. Sample Preparation for LC–MS/MS
Cell lysates were prepared in 4% sodium dodecyl sulfate (SDS)/0.1 M Tris-HCl (pH 7.6).
Proteomic and phosphoproteomic samples were spiked with a super-SILAC mix. Proteomic
samples were also prepared for LF quantitation, which was used as internal validation for
the labeled dataset [20]. All the samples were processed according to the filter-aided sample
preparation (FASP) [49,50]. Only the super-SILAC spiked peptide samples were fractionated using
styrenedivinylbenzene-reversed-phase sulfonate (SDB-RPS) plugs (Empore, 3M, St. Paul, MN, USA) [51].
Immobilized metal affinity chromatography (IMAC) was used for phosphopeptide enrichment [50].
4.3. Nanoflow LC–MS/MS and Data Analysis
Samples were run on a Q Exactive HF Orbitrap coupled to an Ultimate 3000 Rapid Separation
LC system (Thermo Scientific, Waltham, MA, USA). The LC–MS/MS settings have been previously
described [20]. Raw files were processed with MaxQuant software version 1.5.2.8 [52,53], and the Perseus
1.6.1.1 platform was used to analyze and visualize protein groups and phosphosites [20,54].
The LC–MS/MS raw files and MaxQuant output files were deposited in the ProteomeXchange
Consortium via the PRIDE partner repository [55,56] with dataset identifier PXD018359. Proteins
and phosphosites (localization probability > 0.75) with at least five FIRST RELAPSE/DIAGNOSIS
FCs were selected for paired t-test and Z-statistics [57]. GO analysis was performed using a GO
tool [58]. Venn diagrams were made with Biovenn [59]. The amino acid distribution surrounding
the phosphosites was analyzed using iceLogo (p = 0.05) with the sequence windows obtained in
the MaxQuant-generated phosphosite output file [24]. Unregulated phosphosites were used as a
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reference set. Kinase activity estimates were inferred by the KSEA App [20,25,26]. PPI networks
were obtained by using the STRING database version 11 with interactions derived from experiments
and databases at a high confidence score of 0.7 [60]. Networks were visualized using the Cytoscape
platform version 3.7.2 [61]. The ClusterONE plugin was used to identify protein groups of high
cohesiveness [62].
4.4. Western Blots
Western blots for six DIAGNOSIS–FIRST RELAPSE paired samples were performed as described
earlier [20]. Eighteen µg of each sample was employed. The phospho-CDK2 (Thr160) antibody
was purchased from Cell Signaling Technology (Leiden, The Netherlands) and used according to
the manufacturer’s guidelines. Chemiluminescence was measured on a LAS-3000 imager (Fujifilm,
Tokyo, Japan) after membrane incubation with SuperSignal West Atto Ultimate Sensitivity Substrate
(Thermo Scientific). Band intensities for the phosphoprotein were determined by densitometry
software Image J [63]. Band intensities of a protein spotted at approximately 17 kDa on Ponceau-stained
membranes were used for normalization (Figure S3). Statistical analysis was performed using Wilcoxon
matched-pairs singed rank test with GraphPad Prism (San Diego, CA, USA).
5. Conclusions
The comparison between paired samples from AML patients at first diagnosis and at first relapse
showed that relapse was associated with significant increased expression of mitochondrial, ribosomal,
and RNA-processing proteins. The phosphorylation of RNA-binding and -splicing proteins was also
higher in AML cells after relapse. The relapsed AML cells had decreased expression of proteins
involved in intracellular endosomal/secretory vesicle trafficking and cell adhesion.
Thus, although AML patients may be heterogeneous with regard to the primary mechanisms
leading to relapse [9–11], the common features detected in the present study may be a result of
converging effects secondary to the primary mechanisms behind the relapse. The findings suggest
that relapsed AML cells have switched to a state with higher expression of mitochondrial proteins
and activation of CDKs, as well as increased protein synthesis and RNA processing capacity.
In addition, specific changes for subsets or single patient samples were observed, particularly at
the phosphoproteome level. These may represent specific individual changes at first relapse and might
be useful to suggest personalized approaches to target disease recurrence.
Herein, we have shown that LC–MS/MS proteomics technology is also applicable to study
AML relapse. Our recent studies support the use of this strategy at routine level to assist prognosis
and treatment decisions, assuming that the necessary equipment, protocols, software, and expertise
are available.
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